Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Diaphragmatic Recovery in FESS
NCT06982092Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Ain Shams University. Primary endpoint: Difference between diaphragmatic thickening fraction at 30 minutes vs baseline. Started Aug 2024; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT06982092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982092.